Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The dicarbonyl/L-xylulose reductase (DCXR) gene, also known as D-xylulose reductase or aldo-keto reductase (AKR) 1B1, is an enzyme encoded by the DCXR gene. This enzyme belongs to the aldo-keto reductase family, which is a group of enzymes that catalyze the reduction of various aldehydes and ketones to their corresponding alcohols. The DCXR enzyme is particularly known for its role in the metabolism of xylulose, a hexose that is an important intermediate in the metabolic pathways of many organisms, including bacteria, yeast, and plants.
The DCXR enzyme is a member of the aldo-keto reductase family, which is characterized by a conserved catalytic core domain containing a highly conserved N-terminal cysteine, which is involved in the binding of the substrate. The enzyme has a characteristic Rossmann-fold structure that binds the substrate and facilitates the reduction reaction. The DCXR enzyme specifically catalyzes the reduction of xylulose to L-xylose, utilizing NAD(P)H as the cofactor. The enzyme has a Km value of approximately 100 μM for xylulose and a pH optima of around 7.5-8.0.
The DCXR enzyme is involved in various metabolic pathways, including the xylose metabolism pathway in bacteria and yeast, the polyol pathway in plants, and the glycerolipid metabolism in animals. In bacteria and yeast, the DCXR enzyme plays a crucial role in the utilization of xylose, which is a major component of plant cell walls. The enzyme is involved in the conversion of xylose to L-xylose, which is further metabolized to produce energy or used in the synthesis of various biochemicals. In plants, the DCXR enzyme is involved in the polyol pathway, where it reduces xylose to L-xylose, which is then converted to other polyols such as sorbitol and mannitol. In animals, the DCXR enzyme is involved in the glycerolipid metabolism, where it plays a role in the synthesis and breakdown of glycerolipids.
Figure 1. Functional implications of DCXR.
Research on the DCXR gene and its encoded enzyme has revealed its involvement in various physiological and pathological processes. In recent years, the enzyme has gained attention for its potential role in the development and progression of various diseases, including diabetes, obesity, and cancer.
Diabetes is a metabolic disorder characterized by hyperglycemia, which can lead to various complications such as neuropathy, nephropathy, and retinopathy. The DCXR enzyme has been found to be upregulated in diabetes, where it plays a role in the conversion of xylose to L-xylose, which is then used in the synthesis of polyols. Increased levels of polyols have been associated with diabetic complications, suggesting that the DCXR enzyme may contribute to the development of diabetes and its complications.
Obesity is a global health issue that has been linked to various metabolic disorders, including diabetes and cardiovascular diseases. Research has shown that the DCXR enzyme is upregulated in obese individuals, where it plays a role in the synthesis of fatty acids and triacylglycerols. Increased levels of fatty acids and triacylglycerols have been associated with obesity and the development of metabolic syndrome, suggesting that the DCXR enzyme may contribute to the pathogenesis of obesity and related metabolic disorders.
Cancer is a leading cause of death worldwide, and its development has been linked to various factors, including oxidative stress and inflammation. Recent studies have shown that the DCXR enzyme is upregulated in various cancer types, where it plays a role in the reduction of reactive oxygen species (ROS) and other aldehydes. Increased levels of ROS have been associated with cancer development and progression, suggesting that the DCXR enzyme may contribute to the pathogenesis of cancer and its related complications.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.